Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Paradigm Biocapital Advisors LP reported a 5.00% stake in Lexeo Therapeutics, Inc. (Schedule 13G)
Event Nov 13, 2025 · Filed Nov 20, 2025
Paradigm Biocapital Advisors LP reported a 5.00% stake in Lexeo Therapeutics, Inc., 3,671,999 shares, as a passive investor on Nov 13, 2025. Filed Nov 20, 2025 (Schedule 13G).
- Stake
- 5.00%
- Shares
- 3,671,999
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Paradigm BioCapital Advisors LP | 5.00% | 3,671,999 |
| Paradigm BioCapital Advisors GP LLC | 5.00% | 3,671,999 |
| Senai Asefaw, M.D. | 5.00% | 3,671,999 |
| Paradigm BioCapital International Fund Ltd. | 4.40% | 3,244,093 |
Source
Related
- Lexeo Therapeutics, Inc.
- Paradigm Biocapital Advisors LP
- Lexeo Therapeutics, Inc. shareholders
- Schedule 13G/A · Paradigm Biocapital Advisors LP · Aug 14, 2026
- Schedule 13G/A · Paradigm Biocapital Advisors LP · May 15, 2026
- Schedule 13G/A · Paradigm Biocapital Advisors LP · Feb 17, 2026
- Schedule 13G · JPMorgan Chase & Co · Oct 13, 2026
- Form 4 · Bhalla Narinder Pal · Sep 28, 2026
- Form 4 · Otero Jose Manuel · Sep 28, 2026
- Form 4 · Townsend Richard Nolan · Sep 28, 2026
- Form 4 · Tamayo Louis Edward · Aug 19, 2026